Stereotactic ablative body radiotherapy for ventricular tachycardia: An alternative therapy for refractory patients
1Department of Radiation Oncology, Ramón y Cajal Hospital; Madrid-Spain
2Department of Internal Medicine, Ramón y Cajal Hospital; Madrid-Spain
Anatol J Cardiol 2021; 12(25): 858-862 DOI: 10.5152/AnatolJCardiol.2021.187
Full Text PDF

Abstract

Stereotactic ablative body radiotherapy (SABR) allows the administration of ablative doses of radiation in a focused form with a low probability of side effects and is widely used for cancer treatment. However, in the recent years its usefulness in benign cardiac pathology is being studied. In this study, we aimed to guide the cardiologist in SABR and its applications in treatment of refractory ventricular tachycardia. In this review, we analyzed published literature on PubMed and MEDLINE with papers published in the past 5 years. We included papers in the English language with information about indications, radiotherapy plan, doses and fractionations, and outcomes. All citations were evaluated for relevant content and validation.